GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Education
    • Master Theses
    • PhD Theses
  • Services
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Archives for Vinken L

Earlier initiation of antiretroviral treatment coincides with an initial control of the HIV-1 sub-subtype F1 outbreak among men-having-sex-with-men in Flanders, Belgium

  • Autores: Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K
  • Ano de Publicação: 2019
  • Journal: Frontiers in Microbiology
  • Link: https://www.ncbi.nlm.nih.gov/pubmed/30972053

Human immunodeficiency virus type 1 (HIV-1) non-B subtype infections occurred in Belgium since the 1980s, mainly amongst migrants and heterosexuals, whereas subtype B predominated in men-having-sex-with-men (MSM). In the last decade, the diagnosis of F1 sub-subtype in particular has increased substantially, which prompted us to perform a detailed reconstruction of its epidemiological history. To this […]
Ler mais

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium

  • Autores: Alexiev I, Balotta C, Debaisieux L, Devaux C, Fransen K, García Ribas S, Gomes P, Incardona F, Kaiser R, Lemey P, Paraschiv S, Paredes R, Peeters M, Pineda-Peña AC, Ruelle J, Sayan M, Sönnerborg A, Van den Wijngaert S, Van Laethem K, Van Ranst M, Vancutsem E, Vandamme AM, Verhofstede C, Vinken L
  • Ano de Publicação: 2017
  • Journal: Virus Evolution
  • Link: https://academic.oup.com/ve/article/3/suppl_1/vew036.020/4090767%20

HIV-1 non-B subtype infections have been observed in Belgium since the 1980s. However, subtype B predominates amongst men having sex with men (MSM), whereas other subtypes are mainly associated with sub-Saharan African migrants and heterosexual risk behavior. In the last decade, subtype F1 diagnoses have increased substantially in Belgium, representing 9% of newly diagnosed and […]
Ler mais

High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba

  • Autores: Aleman Y, Álvarez D, Aragonés C, Campos J, Correa C, Fonseca C, Kourí V, Limia C, Perez J, Perez L, Schrooten Y, Soto Y, Van Laethem K, Vandamme AM, Vinken L
  • Journal: Journal of Clinical Virology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25397499

INTRODUCTION:
Emergence of HIV-1 drug resistance may limit the sustained benefits of antiretroviral therapy (ART) in settings with limited laboratory monitoring and drug options. The objective is to implement the surveillance of drug resistance and subtypes in HIV-1 patients failing ART in Cuba.
Ler mais

Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba

  • Autores: Abrahantes Y, Aleman Y, Alvarez A, Álvarez D, Aragonés C, Beheydt G, Campos J, Correa C, Dekeersmaeker N, Fonseca C, Imbrechts S, Kourí V, Martínez O, Perez J, Perez L, Schrooten Y, Soto Y, Van Laethem K, Vandamme AM, Vinken L
  • Ano de Publicação: 2013
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23416260

In Cuba, antiretroviral therapy rollout started in 2001 and antiretroviral therapy coverage has reached almost 40% since then. The objectives of this study were therefore to analyze subtype distribution, and level and patterns of drug resistance in therapy-naive HIV-1 patients.
Ler mais

Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences

  • Autores: Megens S, Schrooten Y, Vandamme AM, Vinken L, Van Laethem K
  • Journal: Journal of Virological Methods
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23748120

Genotypic drug resistance testing is routine practice in HIV-1 clinical care. The visual interpretation of sequencing electropherograms is labour-intensive and subject to intra- and inter-assay variability because decisions are based on operators’ judgments. In this study the performance of the automatic editing tool RECall was compared to the current standard of editing manually and editing using the tool ViroSeq.
Ler mais

  • 1
  • 2
  • Next Page »

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013